Rare Medical News
Advertisement
Spotlight On
Myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles
Prevalence
1-9 / 1,000,000
3,310-29,790
US Estimated
5,135-46,215
Europe Estimated
Age of Onset
ICD-10
G70.0
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
5 Facts you should know
FACT
The clinical hallmark of MG is the presence of fluctuating fatigable muscle weakness that worsens with activity and improves on rest
FACT
It most commonly impacts young adult females (under 40) and older males (over 60), but it can occur at any age, including childhood
FACT
MG is caused by an antibody-mediated blockade of neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue
FACT
The ocular and bulbar muscles are affected most commonly and most severely, but most patients also develop some degree of fluctuating generalized weakness
FACT
MG is idiopathic in most patients
Interest over time
Google searches
Common signs & symptoms
Abnormality of the thymus
Acetylcholine receptor antibody positivity
Bulbar palsy
Diplopia
Dysarthria
Dysphagia
Dyspnea
Muscle specific kinase antibody positivity
Current treatments
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.
| Brand name | Generic name | Manufacturer |
|---|---|---|
| Rystiggo | rozanolixizumab-noli | UCB |
| Soliris | eculizumab | Alexion |
| Ultomiris | ravulizumab-cwvz | Alexionv |
| Vyvgart/Vyvgart Hytrulo | efgartigimod | argenx |
| Zilbrysq | zilucoplan | UCB |